Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL7360481 | 0.93 | NPC1 (0.47) | NPC1RAB9AKMT2ALMNAALDH1A1 | |
| SCHEMBL7846691 | 0.90 | NPC1 (0.46) | NPC1RAB9AKMT2ALMNAALDH1A1 | |
| SCHEMBL2378171 | 0.78 | LMNA (0.60) | NPC1RAB9AKMT2ALMNAALDH1A1 | |
| SCHEMBL12301094 | 0.78 | L3MBTL1 (0.35) | KMT2ALMNAMEN1SMN1; SMN2 | |
| SCHEMBL7049258 | 0.78 | NPC1 (0.40) | NPC1RAB9AKMT2ALMNAALDH1A1 | |
| SCHEMBL29963667 | 0.77 | DRD2 (0.38) | LMNA | |
| SCHEMBL5784672 | 0.75 | PDE4A (0.40) | NPC1RAB9AKMT2ALMNA | |
| SCHEMBL10818853 | 0.75 | KMT2A (0.37) | NPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL5784591 | 0.72 | ALDH1A1 (0.38) | KMT2ALMNAALDH1A1KDM4EMAPT | |
| SCHEMBL10800882 | 0.70 | KMT2A (0.40) | NPC1RAB9AKMT2ALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1270577-B1 | FUROISOQUINOLINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2006-12-06 | — | — | EP | disclosed |
| US-6924292-B2 | Furoisoquinoline derivatives, process for producing the same and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| US-20040092582-A1 | Furoisoquinoline derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-13 | — | — | US | disclosed |
| EP-1270577-A1 | FUROISOQUINOLINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092582-A1 | Furoisoquinoline derivatives, process for producing the same and use thereof | PDE3B, PDE5A, PDE3A | NPC1 3538/4885RAB9A 742/4885KMT2A 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.